Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

Trial Profile

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; FT 500 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Carcinoma; Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms Landmark
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 07 Dec 2019 Results (n=12) published in Fate Therapeutics media Release
    • 25 Sep 2019 Planned number of patients changed from 64 to 76.
    • 06 Aug 2019 According to a Fate Therapeutics media release, first three patients with solid tumour have been treated with multiple doses of FT500 in combination arm. All three patients received three weekly doses of FT500 at 100 million cells per dose in an outpatient setting, which treatment cycle was well-tolerated with no dose-limiting toxicities and no FT500-related serious adverse events reported by investigators.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top